Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.55 |
| ▸ | GRM5 | P41594 | 5/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060020 | 0.86 | KDR (0.47) | KDRGRM5PDGFRBKITKCNH2 | |
| SCHEMBL2060138 | 0.80 | KDR (0.51) | KDRHDAC1HDAC8HDAC6SMYD3 | |
| SCHEMBL2060036 | 0.79 | GRM5 (0.49) | KDRGRM5TTKSMYD3AR | |
| SCHEMBL2060127 | 0.74 | KDR (0.54) | KDRGRM5PDGFRBKITFLT1 | |
| SCHEMBL10082850 | 0.74 | KDR (0.53) | KDRGRM5PDGFRBKITFLT1 | |
| SCHEMBL2060044 | 0.71 | RIPK1 (0.51) | KDRKITTTKHDAC1HDAC8 | |
| SCHEMBL2864026 | 0.71 | KDR (1.00) | KDRGRM5PDGFRBKITFLT1 | |
| SCHEMBL2863745 | 0.70 | KDR (0.82) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL885592 | 0.70 | KDR (0.48) | KDRHDAC1HDAC8HDAC6SMYD3 | |
| SCHEMBL2855519 | 0.69 | KDR (0.75) | KDRPDGFRBKITFLT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| CN-101600714-B | Novel pyrindole kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-21 | — | — | CN | disclosed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| CN-101600714-A | Novel kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-2081928-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008060907-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | IGF1R, FGFR1, FLT1 | KDR 5/4885GRM5 2155/4885PDGFRB 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.